Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS One. 2009 Dec 24;4(12):e8196. doi: 10.1371/journal.pone.0008196.
Adipose tissue grows by two mechanisms: hyperplasia (cell number increase) and hypertrophy (cell size increase). Thiazolidinediones are insulin-sensitizing peroxisome proliferator-activated receptor gamma agonists that are known to affect the morphology of adipose tissue.
In this study, adipose cell-size probability distributions were measured in six Zucker fa/fa rats over a period of 24 days, from four weeks of age, using micro-biopsies to obtain subcutaneous (inguinal) fat tissue from the animals. Three of the rats were gavaged daily with rosiglitazone, a thiazolidinedione, and three served as controls. These longitudinal probability distributions were analyzed to obtain the rate of increase in cell-size diameter in rosiglitazone-treated animals, and the hyperplasia induced by treatment quantitatively.
We found that treatment leads to hypertrophy that leads to an approximately linear rate of cell diameter increase (2 m/day), and that the hyperplasia evident in treated animals occurs largely within the first eight days of treatment. The availability of additional lipid storage due to treatment may alleviate lipotoxicity and thereby promote insulin sensitivity. The hypothesis that a TZD regimen involving repeated treatments of limited duration may suffice for improvements in insulin sensitivity merits further investigation.
脂肪组织通过两种机制生长:增生(细胞数量增加)和肥大(细胞大小增加)。噻唑烷二酮类药物是胰岛素增敏的过氧化物酶体增殖物激活受体 γ 激动剂,已知其会影响脂肪组织的形态。
在这项研究中,通过对动物进行微活检,从皮下(腹股沟)脂肪组织中获取组织,在 24 天的时间里,从 4 周龄开始,对六只 Zucker fa/fa 大鼠的脂肪细胞大小概率分布进行了测量。其中 3 只大鼠每天给予罗格列酮(一种噻唑烷二酮类药物)灌胃,3 只作为对照。对这些纵向概率分布进行了分析,以获得罗格列酮处理动物中细胞大小直径增加的速率,并定量分析治疗引起的增生。
我们发现,治疗导致肥大,从而导致细胞直径的线性增加(每天 2 微米),并且在治疗动物中明显的增生主要发生在治疗的前 8 天内。由于治疗而增加的额外脂质储存可能减轻脂毒性,从而促进胰岛素敏感性。关于涉及有限次数重复治疗的 TZD 方案可能足以改善胰岛素敏感性的假设值得进一步研究。